We are live on ! Find out more

Fractyl Health

GUTS

Market cap $13M

0.9765 USD

-0.0150

1.51%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

0.9800

+0.0035

0.36%

1 day

-1.51%

5 days

-9.58%

1 month

-85.05%

3 months

-88.21%

6 months

-87.24%

Year to date

-96.38%

1 year

-93.38%

5 years

-99.37%

10 years

-99.37%

About: Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.

Employees: 73

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 1.7%

Neutral 98.3%

Negative 0%

Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization

BURLINGTON, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced additions to its U.S. patent portfolio that strengthen the intellectual property foundation for investigational Revita® as the Company advances toward a planned U.S. Food and Drug Administration (FDA) De Novo marketing submission for post-GLP-1 weight maintenance.

Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization

Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance

Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain One-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure over continued GLP-1 medication A one-time procedure and freedom from daily or weekly medication were the most frequently selected positive attributes, supporting commercial planning for Revita BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced findings from company-sponsored market research highlighting strong patient interest in a one-time procedural approach to weight maintenance following GLP-1 therapy.

Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance

Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance

Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity Company discontinuing development of Rejuva candidates and seeking strategic alternatives to maximize the value of its Rejuva gene therapy program Cash runway extended into Q2 2027; quarterly operating cash burn expected to be reduced by ~50% to approximately $8 million by end of Q2 2027 BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it is sharpening its focus and concentrating its financial and operational resources on advancing Revita®, its lead product candidate, toward potential U.S. Food and Drug Administration (FDA) marketing authorization and commercialization in post-GLP-1 weight maintenance.

Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance

Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) and certain officers.   The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS

GUTS CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Fractyl (NASDAQ: GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

NEW YORK--(BUSINESS WIRE)---- $GUTS #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. ("“Fractyl” or the “Company”) (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The fi.

GUTS CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Fractyl (NASDAQ: GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm

Fractyl Health, Inc. (NASDAQ: GUTS) shareholders should email [email protected] NEW YORK, Oct. 19, 2026 /PRNewswire/ -- What is the Investigation About? On January 29, 2026, before the market opened, Fractyl Health, Inc. announced six-month data from its REMAIN-1 Midpoint Cohort evaluating Revita for weight maintenance after discontinuation of GLP-1 therapy.

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm

GUTS DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fractyl between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 19, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. (""Fractyl" or the "Company") (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

GUTS DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

Deadline Alert: Fractyl Health, Inc. Investors Have Until October 20, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds

Class action covers investors who bought Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026; complaint alleges the company failed to disclose material adverse facts Class action covers investors who bought Fractyl Health, Inc. securities between January 13, 2025 and January 29, 2026; complaint alleges the company failed to disclose material adverse facts

Deadline Alert: Fractyl Health, Inc. Investors Have Until October 20, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds

Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Fractyl (GUTS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/20/2026

Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS

Two named officers of Fractyl Health, Inc. — Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data, after GUTS shares lost approximately 74.86% of their value across two trading days. Two named officers of Fractyl Health, Inc. — Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data, after GUTS shares lost approximately 74.86% of their value across two trading days.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS

See News Rankings

Price charts implemented using Lightweight Charts™